Thyrocare Technologies Ltd
NSE:THYROCARE
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
63.6B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
97.3B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
65.2B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
74.6B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
29.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24.2B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.3B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.2B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.9B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Thyrocare Technologies Ltd is 73.2%, which is above its 3-year median of 70.9%.
Over the last 3 years, Thyrocare Technologies Ltd’s Gross Margin has increased from 68.7% to 73.2%. During this period, it reached a low of 68.4% on Mar 31, 2023 and a high of 73.2% on Jan 1, 2026.
